$17M in New SAMHSA Grants for SUD Treatment and Recovery for Pregnant and Postpartum Women

The Substance Abuse and Mental Health Services Administration (SAMHSA) has announced $17 million in funding for the Services Grant Program for Residential Treatment for Pregnant and Postpartum Women and the State Pilot Grant Program for Treatment for Pregnant and Postpartum Women, two programs that support substance use disorder (SUD) services for pregnant and postpartum women. The Services Grant Program for Residential Treatment for Pregnant and Postpartum Women will grant $11.6 million to SUD treatment services, recovery support services, and harm reduction interventions across specialty residential and outpatient care, and will also support activities for minor children, partners and other extended family members of pregnant and postpartum women. The State Pilot Grant Program for Treatment for Pregnant and Postpartum Women will grant $5.4 million for family-based treatment services for pregnant and postpartum women with an SUD diagnosis in nonresidential settings, and will also promote new models of service delivery by supporting a coordinated state system managed by state substance agencies. In a press release, Health and Human Services Assistant Secretary for Mental Health and Substance Use and the leader of SAMHSA, Dr. Miriam E. Delphin-Rittmon said, “SAMHSA is committed to expanding access to evidence-based treatments and recovery supports to address overdose and substance misuse to every demographic and community throughout the United States. These grant programs support recovery efforts during and after pregnancy, and they bolster support for families in the areas of substance use prevention and treatment.”

Articles & Resources

SAMHSA – SAMHSA Announces Funding Opportunities for Grants Addressing Substance Misuse, Substance Use Disorder Treatment and Recovery among Pregnant, Postpartum Women

FDA Advisory Committee to Discuss Postmarketing Requirement for Opioids

The Food and Drug Administration (FDA) has issued a Federal Register notice announcing an advisory committee meeting of the Anesthetic and Analgesic Drug Products Advisory Committee to evaluate long-term efficacy of opioid analgesics and the risk of opioid-induced hyperalgesia. The Committee will meet on April 19th to discuss postmarketing requirement (PMR) 3033-11, which requires that new drug applicants “conduct a clinical trial to estimate the serious risk for the development of hyperalgesia following the long-term use of extended-release and long-acting opioid analgesics for at least one year to treat chronic pain.” PMR 3033-11 also requires that the applicant assess risk relative to efficacy, and the Committee will focus their discussions on clinical trial design as it relates to efficacy and risk. FDA will establish a public docket for comments in March.

Articles & Resources

FDA – April 19, 2023: Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee Meeting Announcement

What We Read Last Week

Several articles were published last week pertaining to the opioid epidemic, covering a variety of different components of the topic. Links to relevant articles are provided below.

Clinical Pain Advisor – State Opioid Prescribing Limits Did Not Reduce Duration of Opioid Prescribing by Dentists

Congressman David Trone – Congressman David Trone Releases Statement on President Biden’s Push to End the Opioid Crisis

FDA – Access to Naloxone Can Save a Life During an Opioid Overdose

JAMA – A 2023 Agenda for Substance Use Prevention and Treatment in the US

MIT News – A new educational program for scientists working on substance use disorder

Politico – Teen overdose deaths lead California schools to stock reversal drug

Rand Corporation – An Exploratory Analysis of Differential Prescribing of High-Risk Opioids by Insurance Type Among Patients Seen by the Same Clinician

Senator Bernie Sanders – In Remarks to Advocates, Sanders Proposes Major Expansion of Community Health Centers

Senator Dick Durbin – Durbin, Collins Introduce Siren Reauthorization Act To Support EMS Agencies In Rural Communities

Senator Susan Collins – A New Tool to Help Reduce Non-fatal and Fatal Drug Overdoses

This Week’s Calendar

FDA Advisory Committee on NARCAN
Joint Meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee Meeting Announcement
Wednesday, February 15; 9:00 a.m.; Meeting Notice

Questions about the above content can be directed to [email protected].